cellular proliferation Search Results


94
TargetMol mitogen activated protein kinase mapk pathway inhibitors
Mitogen Activated Protein Kinase Mapk Pathway Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mitogen activated protein kinase mapk pathway inhibitors/product/TargetMol
Average 94 stars, based on 1 article reviews
mitogen activated protein kinase mapk pathway inhibitors - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

92
Rockland Immunochemicals cellcounteztm cell survival assay kit
Cellcounteztm Cell Survival Assay Kit, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cellcounteztm cell survival assay kit/product/Rockland Immunochemicals
Average 92 stars, based on 1 article reviews
cellcounteztm cell survival assay kit - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Klean Industries crypt length, crypt cellularity and crypt cell proliferation
Crypt Length, Crypt Cellularity And Crypt Cell Proliferation, supplied by Klean Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crypt length, crypt cellularity and crypt cell proliferation/product/Klean Industries
Average 90 stars, based on 1 article reviews
crypt length, crypt cellularity and crypt cell proliferation - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Genentech inc in-vitro cellular proliferation assay
In Vitro Cellular Proliferation Assay, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/in-vitro cellular proliferation assay/product/Genentech inc
Average 90 stars, based on 1 article reviews
in-vitro cellular proliferation assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
SAS institute cellular proliferation
Cellular Proliferation, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cellular proliferation/product/SAS institute
Average 90 stars, based on 1 article reviews
cellular proliferation - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Promega mts cellular proliferation-viability assay
Mts Cellular Proliferation Viability Assay, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mts cellular proliferation-viability assay/product/Promega
Average 90 stars, based on 1 article reviews
mts cellular proliferation-viability assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BioCarta inhibition of cellular proliferation by gleevec
Pathway analysis performed using topologyGSA statistical test on graphite networks.
Inhibition Of Cellular Proliferation By Gleevec, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inhibition of cellular proliferation by gleevec/product/BioCarta
Average 90 stars, based on 1 article reviews
inhibition of cellular proliferation by gleevec - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BUCHI AG gastrointestinal cellular proliferation
Pathway analysis performed using topologyGSA statistical test on graphite networks.
Gastrointestinal Cellular Proliferation, supplied by BUCHI AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gastrointestinal cellular proliferation/product/BUCHI AG
Average 90 stars, based on 1 article reviews
gastrointestinal cellular proliferation - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Promega celltiter 96 molecular & cellular proteomics 15.3 1121 non-radioactive cell proliferation assay kit
Pathway analysis performed using topologyGSA statistical test on graphite networks.
Celltiter 96 Molecular & Cellular Proteomics 15.3 1121 Non Radioactive Cell Proliferation Assay Kit, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/celltiter 96 molecular & cellular proteomics 15.3 1121 non-radioactive cell proliferation assay kit/product/Promega
Average 90 stars, based on 1 article reviews
celltiter 96 molecular & cellular proteomics 15.3 1121 non-radioactive cell proliferation assay kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BioCarta h_gleevecpathway:inhibition of cellular proliferation by gleevec
Over-represented annotation terms in genes selected by CASh.
H Gleevecpathway:Inhibition Of Cellular Proliferation By Gleevec, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h_gleevecpathway:inhibition of cellular proliferation by gleevec/product/BioCarta
Average 90 stars, based on 1 article reviews
h_gleevecpathway:inhibition of cellular proliferation by gleevec - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Advanced Cellular Dynamics Inc cell proliferation assay
Over-represented annotation terms in genes selected by CASh.
Cell Proliferation Assay, supplied by Advanced Cellular Dynamics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell proliferation assay/product/Advanced Cellular Dynamics Inc
Average 90 stars, based on 1 article reviews
cell proliferation assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Promega nonradioactive colorimetric cellular proliferation assay
Effects of cytoskeletal inhibitors on HIV-1 release and viral infectivity. JurkatLAI cells were either left untreated or treated with 1 μM of nocodazole, colchicine, cytochalasin D, or latrunculin for 3 h at 37°C. (A) Cell and viral lysates from untreated or inhibitor-treated cells were separated by SDS-PAGE, and HIV-1 Gag was detected by Western blotting. C, lysates prepared from cell pellets; V, lysates prepared from cell-free virus-containing supernatants. For each condition, 20 μg of cell lysate was used and an equal volume of viral lysate was loaded to allow a direct comparison of virus outputs. The Gag polyprotein p55 and the capsid protein p24 are indicated. (B) Densitometer analysis was performed on Gag p55 and p24 bands from nonsaturated Western blots, and for each treatment condition, the ratio of total cell-free to total cell-associated Gag was calculated. Values are the averages for three independent virus release assays, and the error bars show the SEM. (C) Env incorporation into HIV-1 virions from cells treated with cytoskeletal inhibitors. Supernatants were harvested from JurkatLAI cells that were either left untreated or treated with cytoskeletal inhibitors for 3 h, and virions were concentrated by centrifugation. Viral lysates were separated by SDS-PAGE, and HIV-1 Env was detected by Western blotting with rabbit anti-gp120 serum. A representative blot is shown. (D) Densitometer analysis was performed on gp120 bands from nonsaturated blots. Values are the average pixel intensities of individual bands corresponding to gp120 and are the averages for two independent virus release experiments. Error bars show the SEM. (E) Infectivity assay on viral supernatants harvested from inhibitor-treated cells. JurkatLAI cells were either left untreated (white bar) or treated for 3 h with cytoskeletal inhibitors (gray bars). The cells were then washed to remove inhibitors and incubated for 1 h at 37°C, and virus-containing supernatants were collected and used to infect HeLa reporter cells. Viral infectivity was measured by performing a β-galactosidase assay, and values show the percentages of infectivity relative to that of the untreated control, which was normalized to 100%. Data are the averages for two independent virus release assays, and error bars show the SEM. (F) After 3 h of incubation in the presence or absence of inhibitors, the number of viable JurkatLAI cells was calculated by trypan blue exclusion. Error bars show the standard deviations (SD) for a single experiment performed in triplicate. (G) The metabolic activity of treated or untreated cells was determined using a nonradioactive <t>colorimetric</t> cellular <t>proliferation</t> assay (Promega) that measures bioreduction of the MTS tetrazolium compound. The absorbance at 490 nm was measured, and values are shown for each inhibitor and the untreated control. Error bars show the SD.
Nonradioactive Colorimetric Cellular Proliferation Assay, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonradioactive colorimetric cellular proliferation assay/product/Promega
Average 90 stars, based on 1 article reviews
nonradioactive colorimetric cellular proliferation assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Pathway analysis performed using topologyGSA statistical test on graphite networks.

Journal: BMC Bioinformatics

Article Title: g raphite - a Bioconductor package to convert pathway topology to gene network

doi: 10.1186/1471-2105-13-20

Figure Lengend Snippet: Pathway analysis performed using topologyGSA statistical test on graphite networks.

Article Snippet: 38 , inhibition of cellular proliferation by gleevec , 0.04 , Biocarta , , .

Techniques: Activation Assay, Migration, Infection, Binding Assay, Inhibition

Over-represented annotation terms in genes selected by CASh.

Journal: BMC Bioinformatics

Article Title: Combining Shapley value and statistics to the analysis of gene expression data in children exposed to air pollution

doi: 10.1186/1471-2105-9-361

Figure Lengend Snippet: Over-represented annotation terms in genes selected by CASh.

Article Snippet: BIOCARTA , h_gleevecpathway:Inhibition of Cellular Proliferation by Gleevec , 4,446 , 0,051.

Techniques: Activity Assay, Binding Assay, Ubiquitin Proteomics, Mutagenesis, Conjugation Assay, Membrane, Gene Expression

Effects of cytoskeletal inhibitors on HIV-1 release and viral infectivity. JurkatLAI cells were either left untreated or treated with 1 μM of nocodazole, colchicine, cytochalasin D, or latrunculin for 3 h at 37°C. (A) Cell and viral lysates from untreated or inhibitor-treated cells were separated by SDS-PAGE, and HIV-1 Gag was detected by Western blotting. C, lysates prepared from cell pellets; V, lysates prepared from cell-free virus-containing supernatants. For each condition, 20 μg of cell lysate was used and an equal volume of viral lysate was loaded to allow a direct comparison of virus outputs. The Gag polyprotein p55 and the capsid protein p24 are indicated. (B) Densitometer analysis was performed on Gag p55 and p24 bands from nonsaturated Western blots, and for each treatment condition, the ratio of total cell-free to total cell-associated Gag was calculated. Values are the averages for three independent virus release assays, and the error bars show the SEM. (C) Env incorporation into HIV-1 virions from cells treated with cytoskeletal inhibitors. Supernatants were harvested from JurkatLAI cells that were either left untreated or treated with cytoskeletal inhibitors for 3 h, and virions were concentrated by centrifugation. Viral lysates were separated by SDS-PAGE, and HIV-1 Env was detected by Western blotting with rabbit anti-gp120 serum. A representative blot is shown. (D) Densitometer analysis was performed on gp120 bands from nonsaturated blots. Values are the average pixel intensities of individual bands corresponding to gp120 and are the averages for two independent virus release experiments. Error bars show the SEM. (E) Infectivity assay on viral supernatants harvested from inhibitor-treated cells. JurkatLAI cells were either left untreated (white bar) or treated for 3 h with cytoskeletal inhibitors (gray bars). The cells were then washed to remove inhibitors and incubated for 1 h at 37°C, and virus-containing supernatants were collected and used to infect HeLa reporter cells. Viral infectivity was measured by performing a β-galactosidase assay, and values show the percentages of infectivity relative to that of the untreated control, which was normalized to 100%. Data are the averages for two independent virus release assays, and error bars show the SEM. (F) After 3 h of incubation in the presence or absence of inhibitors, the number of viable JurkatLAI cells was calculated by trypan blue exclusion. Error bars show the standard deviations (SD) for a single experiment performed in triplicate. (G) The metabolic activity of treated or untreated cells was determined using a nonradioactive colorimetric cellular proliferation assay (Promega) that measures bioreduction of the MTS tetrazolium compound. The absorbance at 490 nm was measured, and values are shown for each inhibitor and the untreated control. Error bars show the SD.

Journal:

Article Title: Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1

doi: 10.1128/JVI.01469-06

Figure Lengend Snippet: Effects of cytoskeletal inhibitors on HIV-1 release and viral infectivity. JurkatLAI cells were either left untreated or treated with 1 μM of nocodazole, colchicine, cytochalasin D, or latrunculin for 3 h at 37°C. (A) Cell and viral lysates from untreated or inhibitor-treated cells were separated by SDS-PAGE, and HIV-1 Gag was detected by Western blotting. C, lysates prepared from cell pellets; V, lysates prepared from cell-free virus-containing supernatants. For each condition, 20 μg of cell lysate was used and an equal volume of viral lysate was loaded to allow a direct comparison of virus outputs. The Gag polyprotein p55 and the capsid protein p24 are indicated. (B) Densitometer analysis was performed on Gag p55 and p24 bands from nonsaturated Western blots, and for each treatment condition, the ratio of total cell-free to total cell-associated Gag was calculated. Values are the averages for three independent virus release assays, and the error bars show the SEM. (C) Env incorporation into HIV-1 virions from cells treated with cytoskeletal inhibitors. Supernatants were harvested from JurkatLAI cells that were either left untreated or treated with cytoskeletal inhibitors for 3 h, and virions were concentrated by centrifugation. Viral lysates were separated by SDS-PAGE, and HIV-1 Env was detected by Western blotting with rabbit anti-gp120 serum. A representative blot is shown. (D) Densitometer analysis was performed on gp120 bands from nonsaturated blots. Values are the average pixel intensities of individual bands corresponding to gp120 and are the averages for two independent virus release experiments. Error bars show the SEM. (E) Infectivity assay on viral supernatants harvested from inhibitor-treated cells. JurkatLAI cells were either left untreated (white bar) or treated for 3 h with cytoskeletal inhibitors (gray bars). The cells were then washed to remove inhibitors and incubated for 1 h at 37°C, and virus-containing supernatants were collected and used to infect HeLa reporter cells. Viral infectivity was measured by performing a β-galactosidase assay, and values show the percentages of infectivity relative to that of the untreated control, which was normalized to 100%. Data are the averages for two independent virus release assays, and error bars show the SEM. (F) After 3 h of incubation in the presence or absence of inhibitors, the number of viable JurkatLAI cells was calculated by trypan blue exclusion. Error bars show the standard deviations (SD) for a single experiment performed in triplicate. (G) The metabolic activity of treated or untreated cells was determined using a nonradioactive colorimetric cellular proliferation assay (Promega) that measures bioreduction of the MTS tetrazolium compound. The absorbance at 490 nm was measured, and values are shown for each inhibitor and the untreated control. Error bars show the SD.

Article Snippet: Error bars show the standard deviations (SD) for a single experiment performed in triplicate. (G) The metabolic activity of treated or untreated cells was determined using a nonradioactive colorimetric cellular proliferation assay (Promega) that measures bioreduction of the MTS tetrazolium compound.

Techniques: Infection, SDS Page, Western Blot, Virus, Comparison, Centrifugation, Incubation, Control, Activity Assay, Proliferation Assay